An ISO 9001:2015 Certified Firm

Pharmaceutical & Life Sciences

Advanced Microscopic Device

Screen Shot

This technology is based on a slide that has multiple specimen collection points. Each collection point has capable of analyzing each of specimen/sample at a time. All of the collection points will work parallel and independent. This slide can also be customizable by the user, that would allow the specimen collection points to analyze any kind of specimen.

Application Number: 201741032643

For more details about the technology: Click here

Adeno Associated Virus (AAV)

Adeno-associated virus capsid, molecular model. The capsid is a protein shell that encloses the virus' genetic information. Adeno-associated viruses (AAVs) are the smallest known viruses to infect humans. This is serotype 2 of the virus. AAVs do not cause diseases, and only provoke a mild immune response. Because they incorporate their genetic material into a specific location within the host's genome, they have potential as a vector for gene therapy.

AAV is a small virus that infects humans and other primate species. It is not currently known to cause any disease, however, it causes a very mild immune response, lending further support to its apparent lack of pathogenicity. Its genomic structure consists of a replication (rep, left) and capsid (cap, right) gene flanked by two inverted terminal repeats (ITR’s). The rep gene is important for integration of wild AAV onto a specific site on human chromosome 19. So, our goal is to create a recombinant AAV in which the cap gene (and situationally the rep gene) are deleted and replaced by the gene of interest (transgene).

For more details about the technology:  Click here 

Voriconazole Transdermal Spray

voriconazole-transdermal-spray

The patent pertains to the field of Topical pharmaceutical formulation containing Voriconazole. The antifungal microemulgel aims at reducing side effects of the drug combining it with the advantages of emulgel. Voriconazole a triazole antifungal medication is generally used to treat serious, invasive fungal infections like candidiasis aspergillosis etc. The drug is loaded on to microemulgel, which has been prepared by screening of oils, emulsifier, and co-emulsifier on basis of solubility of desirable API in it. Voriconazole has high solubility in Neem oil which also assists in its therapeutic action. Presence of oil portion facilitates better penetration of API in the skin. Oil Micelle Size being less than 500 nm provides more area for absorption of API in the skin enhancing its efficacy. Microemulgel has an advantage of emulgel and micro-emulsion; combining several desirable properties like good consistency, thyrotrophic, greaseless, easily spreadable as well as removable, emollient, non-staining, water soluble, longer shelf-life, bio-friendly, transparent with a pleasant appearance. Indian Patent Application 3386/MUM/2014

More about technology: Click here

Voriconazole Topical Antifungal Microemulgel

voriconazole-topical-antifungal-microemulgel

The invention relates to the formulation of voriconazole topical antifungal microemulgel. As compared to gel and other topical preparations microemulgel has been prepared by screening of oils, emulsifier, and co-emulsifier on bases of solubility of an API in it. An API has high solubility and oil may also have more or less pharmacological property, so it may assist the therapeutic action of API. Due to presence of oil portion, it leads to more penetration of API in the skin. Oil Micelle Size is less than 500 nm which provides more area for absorption of API in the skin so more penetration and more effective than macro-emulsion. Microemulgel has an advantage of emulgel that has dual benefits of micro-emulsion and gel and several other desirable properties like good consistency, thyrotrophic, greaseless, easily spreadable as well as removable, emollient, non-staining, water soluble, longer shelf-life, bio-friendly, transparent, pleasant appearance, ability of patients for self-medication, termination of medications will be easy, etc.
Indian Patent Application 3169/MUM/2014
More about technology: Click here

Safety Isolation Bag For Power Morcellation

safety_isolation_bag

The present innovation relates to “Safety Isolation Bag”, a pneumoperitoneum device for intra-abdominal, endoscopic procedures, power morcellation and vaginal morcellation for facilitating safe removal of body mass from within the abdominal cavity. It comprises of an expandable and collapsible enclosed internal space having a neck portion with mouth having re-tractor means and provided with markings, color coded indicating how much the bag is to be pulled out for the removal of large, medium and small tissue mass, and also having one or more non-return valves attached with long looped threads on one of the surface in the wall of the safety isolation bag below the neck as a means for introducing the surgical instruments and accessories into the enclosed internal space at the right place and to close the puncture hole after the procedure. It is made of one or more layers of flexible biocompatible / medical grade plastic film.
PCT Patent Application No. : PCT/IN2015/000420
For more details about the technology, please visit the website www.safetyisolationbag.com

Blood-based Epigenetic Bio Marker of Human Cancer

BIO MARKER OF HUMAN CANCER

The present invention relates to a novel and ideal bio-marker of human cancer, which meets all three characteristics formulated by the international Predictive Safety Testing Consortium (PSTC) comprising industries, nonprofit organizations and regulators (including FDA and EMEA/EMA). A non-radioactive, highly sensitive, reproducible assay to quantitatively estimate the bio-marker using a minimally invasive quick process that does not require hospitalization has been developed and standardised. The design of a complete and easy-to-use prototype for this test has already been developed in a diagnostic kit that can reliably and reproducibly detect multiple types of cancer within a short time of less than 60 min, using a minimally invasive OPD procedure requiring no hospitalization, and provides quantitative measurements of treatment efficacy and cancer retardation. The novel diagnostic kit is highly reliable and portable to remote locations without compromising efficacy. More about technology: 1791/KOL/2008 Click here